More Workspace for Life Sciences


Vienna - At the site of a former Viennese hospital vize-mayor Sepp Rieder inaugurated the new Vienna Competence Center (VCC) at the end of June. The objective of the center is in biotechnology, medical technology, biomedical sciences, and economy services. The available floor space is about 5,800 sq m and it is already completely booked up. The building was developed and built by PRISMA, Zentrum für Stadtentwicklung GmbH, in co-operation with the City of Vienna. The new building is the first in a larger total project. In future there will be a Life Science Campus at this site.
Over the past years a dynamic life sciences scene has developed in and around Vienna: Since 1998 there were 35 company set-ups. Today some of them have left the start-up-phase. At the end of 2003 there were 70 companies with 6,500 employees in and around Vienna.



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues